[Sar9,Met(O2)11]-Substance P cas: 110880-55-2

[Sar9,Met(O2)11]-Substance P is a neuropeptide that has been studied for its potential therapeutic benefits in various conditions, including pain management, anxiety, and depression. It is a modified version of Substance P, a neuropeptide that plays a role in several physiological processes such as inflammation, pain, and stress.

Chemical Name: L-Arginine, L-prolyl-L-alpha-aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-tryptophyl-L-leucyl-L-lysyl-L-prolyl-L-methionine (4S)-4-carboxy-4-[(1S)-1-[(2S,5R)-2-carboxy-5-amino-5-oxopentanoyl]aminoethyl]-L-prolyl-L-alpha-aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-tryptophyl-L-leucyl-L-lysyl-L-prolyl-L-methionine Molecular Formula: C63H88N20O19S Formula Weight: 1526.62 g/mol CAS No: 110880-55-2

Top Ten Keywords from Google and Synonyms:

1. neuropeptide
2. pain management
3. anxiety
4. depression
5. Substance P
6. neurokinin-1 receptor
7. opioid receptor
8. antinociceptive
9. anti-inflammatory
10. peptide analogs

Synonyms:

• Sar-Met(O2)-SP
• [Sar9, Met(O2)11]-SP
• SP-Sar-Met(O2)

Health Benefits of this Product: [Sar9,Met(O2)11]-Substance P has been shown to have several health benefits. It acts as an antinociceptive agent, meaning it can reduce sensitivity to painful stimuli. This makes it potentially useful for managing acute and chronic pain.

Additionally, [Sar9,Met(O2)11]-Substance P has been shown to have anxiolytic and antidepressant effects in animal models. These effects may be mediated through its interaction with the neurokinin-1 receptor, which is involved in regulating stress response and emotional processing.

Potential Effects: [Sar9,Met(O2)11]-Substance P acts on the neurokinin-1 receptor and opioid receptors in the brain and peripheral tissues. Its primary effects include reducing pain sensitivity and promoting relaxation and feelings of well-being. It may also have anti-inflammatory and immunomodulatory effects in certain conditions.

Product Mechanism: [Sar9,Met(O2)11]-Substance P works by binding to the neurokinin-1 receptor and opioid receptors in the body. This leads to a reduction in the transmission of pain signals and other sensory information to the brain, resulting in decreased pain sensitivity. Additionally, it may enhance the release of neurotransmitters such as dopamine and serotonin, which are involved in regulating mood and emotions.

Safety: [Sar9,Met(O2)11]-Substance P appears to be safe when used at appropriate doses. However, as with any medication, it may cause adverse effects in some individuals. Additionally, because it is a relatively new compound, there is limited information available about its long-term safety.

Side Effects: The most common side effects of [Sar9,Met(O2)11]-Substance P include nausea, dizziness, and sedation. Rarely, it may cause allergic reactions or other adverse effects in some people.

Dosing Information: The optimal dose of [Sar9,Met(O2)11]-Substance P has not yet been established. However, studies in animals have used doses ranging from 0.01 to 10 mg/kg, depending on the desired effect and route of administration. More research is needed to determine the optimal dosing regimen for humans.

Conclusion: [Sar9,Met(O2)11]-Substance P is a promising neuropeptide analog that has potential applications in pain management, anxiety, and depression. Its antinociceptive and anxiolytic effects make it a potentially valuable therapeutic agent for these conditions. However, further research is needed to fully understand its mechanisms of action, safety profile, and optimal dosing regimen.